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ABSTRACT
Objective: Ulcerative colitis is a type of inflammatory bowel disease is a chronic gastrointestinal disorder characterized by intestinal inflammation 
and mucosal tissue damage. We examined the lipid profile levels in murine model of 7,12-dimethylbenz(a)anthracene induced ulcerative colitis.
Methods: Serum was separated from whole blood and was used to determine the lipid profile such as total cholesterol (TC), phospholipids (PL), 
triglycerides (TG), free fatty acids, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C).
Results: Ulcerative colitis rats exhibit a low level of LDL-C and TC. No significant difference was observed in HDL and TG, and significant difference 
was observed in PL and free fatty acid serum levels. This communication highlights the lipid profile that occurs in ulcerative colitis.
Conclusion: This study, thus, provides valuable information about the disturbances in the lipids and lipoproteins occur in ulcerative colitis.
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INTRODUCTION
Ulcerative colitis is a type of inflammatory bowel disease in which 
immune dysregulation promotes development of ulcerations in the 
lining of the colon [1]. It is characterized by recurring episodes of 
inflammation limited to the mucosal layer of the colon; it invariably 
involves the rectum and may extend in a proximal and continuous fashion 
to involve other portions of the colon [2,3]. Main clinical manifestations 
of ulcerative colitis are abdominal pain, diarrhea, mucous, bloody, and 
purulent stools [3,4]. Although the underlying pathogenesis of the 
disease was still unknown, the widely accepted hypothesis was that the 
pathophysiology involves an interaction among immunological, genetic, 
and environmental factors [4]. The inflammatory bowel disease is 
becoming more common in Asia, but epidemiologic data are lacking [5]. 
The highest rates have been reported in India particularly ulcerative 
colitis, Japan, Middle East, and overall rising trends of inflammatory 
bowel disease are seen in East Asia [6].
METHODS
Animal selection
Male Wistar rats (170-200 g) were obtained from the animal house 
of Mannuthy Veterinary College, Thrissur, Kerala. Animals were 
maintained under standard conditions (12 hrs light/dark cycle; 25±3°C, 
45-65% humidity) and had free access to standard rat feed and water 
ad libitum. Animals were grouped as control and induced. Induced 
group was sub-grouped as A, B and induced with 10, and 20 mg/kg body 
weight of 7,12-dimethylbenz(a)anthracene. Animals were sacrificed on 
4th, 8th, 12th, 24th, and 32nd week from the date of induction by cervical 
dislocation. Animal studies were performed according to the prescribed 
guidelines of the committee for the purpose of control and supervision 
of experiments on animals (659/02/a/CPCSEA), Government of India, 
India.
Biochemical analysis
Heparinized blood was collected for analysis and serum was prepared 
from whole blood. The homogenates were centrifuged at 3000 g for 
15 minutes at 4°C for cytosolic separation. Serum was separated from 
whole blood and was used to quantify the lipid profile such as total 
cholesterol (TC) [7], phospholipids (PL) [8], triglycerides (TG) [9], free 
fatty acids [10], and high-density lipoprotein (HDL) [11]. Low-density 
lipoprotein (LDL) was calculated using the following formula:
LDLC=TC−HDL+(TGL/5)
RESULTS AND DISCUSSION
Several differences were noted in plasma lipid profile of ulcerative 
colitis induced rats and control rats (Tables 1 and 2). TC levels were 
significantly reduced. On 32nd week induced group both 10 mg 
and 20 mg showed reclined value when compared with control 
rats (10 mg - 58.67±0.65 mg/dL, and 20 mg - 54.57±0.54 mg/dL vs. 
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Table 1: Effect of DMBA on the levels of lipoprotein in serum of 
control and experimental animals
Groups HDL-C LDL-C
Group I control 42.65±0.65 23.43±0.21
Group II induced
A. 10 mg
1. 4th 42.44±0.45a* 22.14±0.16a*
2. 8th 42.29±0.34a* 19.15±0.23a*
3. 16th 43.14±0.76a* 17.21±0.18a*
4. 24th 42.13±0.89a* 15.27±0.21a*
5. 32nd 41.34±0.23a*,c* 13.91±0.15a*,c*
B. 20 mg
1. 4th 43.56±0.87a*,b* 20.51±0.21a*, b*
2. 8th 41.65±0.24a*,b* 18.11±0.17a*,b*
3. 16th 42.33±0.77a*,b* 14.16±0.22a*,b*
4. 24th 43.09±1.23a*,b* 12.62±0.18a*,b*
5. 32nd 42.11±0.43a*,b*,d* 10.19±0.19a*,b*,d*
Values expressed as mean±SD (n=2). *Significant at 5% (p<0.05). Group 
comparison: aGII versus GI, bGIIB versus GIIA, cGIIA5 versus GIIA1, GIIA2, GIIA3 
and GIIA4, dGIIB5 versus GIIB1, GIIB2, GIIB3 and GIIB4. HDL-C: High-density 
lipoprotein cholesterol, LDL-C: Low-density lipoprotein cholesterol, DMBA: 7,12 
Dimethylbenz(a)anthracene, SD: Standard deviation
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control - 72.67±3.67 mg/dL). PL, TG, and free fatty acids showed 
gradual increase in induced group when compare with control rats. 
From 4th week until 32nd week, the values increased steadily. No 
significant changes were observed in HDL-C levels in both 10 mg and 
20 mg group of induced group. Lowering of LDL-C values was observed 
in induced group of both doses against control value (13.91±0.15, and 
10.19±0.19 vs. 23.43±0.21). The data are expressed as mean±standard 
deviation. Statistical comparison was done at significance level, p<0.05 
using SPSS package version 10.0. One-way ANOVA followed by post-hoc 
analysis of least significant difference was performed.
In another study serum concentration of TC, LDL-C was significantly 
lowered when compared with healthy controls.
On the other hand, no significant changes were observed in HDL-C 
levels and TG ulcerative colitis, and healthy subjects [12-15]. PL were 
significantly increased in another study in ulcerative colitis patients 
when compared with healthy subjects [16]. In our study, free fatty acids 
were significantly raised from 4th week until 32nd week in experimental 
rats when compared with control. In another study, there were a 
significant raise in fatty acids in inflammatory bowel disease [17-19]. 
In conclusion, ulcerative colitis rats exhibit lower levels of TC and 
LDL-C compared to healthy subjects. In addition, no significant changes 
seen in HDL-C and TG. High level of free fatty acids and PL found when 
compared with healthy rats. This proves the link between the lipid 
alteration and ulcerative colitis disease. However, more large-scale 
studies should be carried to reach the robust conclusions about the 
lipid alterations reported in ulcerative colitis.
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Table 2: Effect of DMBA on the levels of lipids in serum of control and experimental animals
Groups TC mg/dL Phospholipids mg/dL TG mg/dL Free fatty acids mg/dL
Group I control 72.67±3.67 66.33±1.43 40.54±1.12 86.55±2.65
Group II induced
A. 10 mg
1. 4th 70.35±0.14a* 73.76±0.44a* 41.12±0.63a* 90.12±0.35a*
2. 8th 67.31±0.26a* 75.44±0.23a* 40.22±0.66a* 94.35±0.67a*
3. 16th 63.22±0.43a* 96.43±0.54a* 41.01±0.82a* 114.51±0.39a*
4. 24th 61.35±0.73a* 97.26±0.89a* 41.12±0.32a* 114.78±0.54a*
5. 32nd 58.67±0.65a*,c* 97.33±0.34a*,c* 40.45±0.52a*,c* 115.78±0.17a*,c*
B. 20 mg  
1. 4th 66.32±0.87a*,b* 75.65±0.45a*b* 40.66±0.35a*,b* 92.45±0.89a*,b*
2. 8th 64.34±0.11a*,b* 78.34±0.56a*,b* 41.44±0.89a*,b* 97.23±0.34a*,b*
3. 16th 60.23±0.29a*,b* 100.28±0.54a*,b 41.39±0.56a*,b* 118.09±0.90a*,b*
4. 24th 57.87±0.32a*,b* 101.56±0.48a*,b* 42.01±0.45a*,b* 124.34±0.48a*,b*
5. 32nd 54.57±0.54a*,b*,d* 102.45±0.22a*,b*,d* 41.45±0.73a*,b*,d* 126.67±0.67a*,b*,d*
Values expressed as mean±SD (n=2). *Significant at 5% (p<0.05), Group comparison: aGII versus GI, bGIIB versus GIIA, cGIIA5 versus GIIA1, GIIA2, GIIA3 and GIIA4, 
dGIIB5 versus GIIB1, GIIB2, GIIB3 and GIIB4, TC: Total cholesterol, TG: Triglycerides, DMBA: 7,12 dimethylbenz(a)anthracene
